Nitrosative Injury and Antioxidant Therapy in the Management of Diabetic Neuropathy

Journal of Investigative Medicine

Volumn 52, Issue 1, 2004, Pages 33-44

  Cowell, Rita M ^a   Russell, James W ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Apoptosis; Diabetes; Neuron; Nitric oxide; Oxidative stress; Superoxides

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; FIDARESTAT; GLUCOSE; GROWTH FACTOR; LIPID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROSO DERIVATIVE; PEROXYNITRITE; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT NERVE GROWTH FACTOR; RETINOL; SOMATOMEDIN C; SUPEROXIDE; THIOCTIC ACID; ZENARESTAT;

ANIMAL; CELL DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DISEASE MODEL; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; ISCHEMIA; LIPID PEROXIDATION; METABOLISM; NEPHROTOXICITY; NERVE CELL; NERVE CELL NECROSIS; NERVE INJURY; NEUROPROTECTION; NEUROTOXICITY; NITRATION; NITROSATION; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; POLYNEUROPATHY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIDE EFFECT; SPINAL GANGLION; VASODILATATION;

ANIMALIA;

EID: 1342346538     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-01-24     Document Type: Conference Paper

References (139)

1. Greene DA, Stevens MJ, Feldman EL. Glycemic control. In: Dyck PJ, Thomas PK, editors. Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders; 1998:297-315.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
3. Albers JW, Kenny DJ, Brown M, et al. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869-80.
4. Molyneaux LM, Constantino MI, McGill M, et al. Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998;42:77-83.
5. Feldman EL, Russell JW, Sullivan KA, et al. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999;12:553-63.
6. Greene DA, Stevens MJ, Obrosova I, et al. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999;375:217-23.
7. Kim YM, Bombeck CA, Billiar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 1999;84:253-6.
8. Russell JW, Golovoy D, Vincent A, et al. High glucose induced-oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002;16:1738-48.
9. Stevens MJ, Obrosova I, Cao X, et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;49:1006-15.
10. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
12. van Dam PS. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002;18:176-84.
13. Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
14. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med 1999;107(2B):2S-8S.
15. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222-6.
16. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
17. Russell JW, Sullivan KA, Windebank AJ, et al. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999;6:347-63.
18. Russell JW, Golovoy D, Vincent AM, et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002;16:1738-48.
19. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003;52:165-71.
20. Srinivasan S, Stevens MJ, Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000;49:1932-8.
21. Poderoso JJ, Carreras MC, Lisdero C, et al. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 1996;328:85-92.
22. Cowell R, Cherian K, Russell JW. Regulation of neuronal nitric oxide synthase (nNOS) in models of diabetic neuropathy. J Peripheral Nerv Syst 2003;8:1-78.
23. Cowell RM, Cherian K, Russell JW. Regulation of neuronal nitric oxide synthase (nNOS) in models of diabetic neuropathy. The Endocrine Society's 85th Annual Meeting 2003;P1-309:206.
24. Garcia SF, Virag L, Jagtap RP, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-13.
25. Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr Opin Chem Biol 1998;2:656-63.
26. Adak S, Santolini J, Tikunova S, et al. Neuronal nitric-oxide synthase mutant (Ser-1412 →; Asp) demonstrates surprising connections between heme reduction, NO complex formation, and catalysis. J Biol Chem 2001;276:1244-52.
27. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci U S A 1993;90:10769-72.
28. Heneka MT, Feinstein DL. Expression and function of inducible nitric oxide synthase in neurons. J Neuroimmunol 2001;114:8-18.
29. Ghafourifar P, Richter C. Nitric oxide synthase activity in mitochondria. FEBS Lett 1997;418:291-6.
30. Riobo NA, Melani M, Sanjuan N, et al. The modulation of mitochondrial nitric-oxide synthase activity in rat brain development. J Biol Chem 2002;277:42447-55.
31. Leong SK, Ruan RS, Zhang Z. A critical assessment of the neurodestructive and neuroprotective effects of nitric oxide. Ann N Y Acad Sci 2002;962:161-81.
32. Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta 1999;1411:401-14.
33. Raoul C, Estevez AG, Nishimune H, et al. Motoneuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron 2002;35:1067-83.
34. Gonzalez-Zulueta M, Ensz LM, Mukhina G, et al. Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity. J Neurosci 1998;18:2040-55.
35. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
36. Ciani E, Guidi S, Della VG, et al. Nitric oxide protects neuroblastoma cells from apoptosis induced by serum deprivation through cAMP-response element-binding protein (CREB) activation. J Biol Chem 2002;277:49896-902.
37. Gudi T, Casteel DE, Vinson C, et al. NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation. Oncogene 2000;19:6324-33.
38. Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 1999;19:10250-61.
39. Ha KS, Kim KM, Kwon YG, et al. Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J 2003 17:1036-47
40. Tejedo JR, Ramirez Cahuana GM, et al. Evidence for involvement of c-Src in the anti-apoptotic action of nitric oxide in serum-deprived RINm5F cells. Cell Signal 2001;13:809-17.
41. Wang X, Robinson PJ. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem 1997;68:443-56.
42. Moellering D, Mc AJ, Patel RP, et al. The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells a role for gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase. FEBS Lett 1999;448:292-6.
43. Jaffrey SR, Erdjument-Bromage H, Ferris CD, et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001;3:193-7.
44. Foster MW, McMahon TJ, Stamler JS. S-Nitrosylation in health and disease. Trends Mol Med 2003;9:160-8.
45. Marshall HE, Stamler JS. Nitrosative stress-induced apoptosis through inhibition of NF-kappa B. J Biol Chem 2002;277:34223-8.
46. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 2001;40:1688-93.
47. Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J 2000;14:1889-900.
48. Lui L, Stamler JS. NO: an inhibitor of cell death. Cell Death Differ 1999;6:937-42.
49. Radi R, Cassina A, Hodara R, et al. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002;33:1451-64.
50. Cassina AM, Hodara R, Souza JM, et al. Cytochrome c nitration by peroxynitrite. J Biol Chem 2000;275:21409-15.
51. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498-500.
52. Eu JP, Liu L, Zeng M, et al. An apoptotic model for nitrosative stress. Biochemistry 2000;39:1040-7.
53. Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nat Struct Biol 1998;5:247-9.
54. Thippeswamy T, Morris R. The roles of nitric oxide in dorsal root ganglion neurons. Ann N Y Acad Sci 2002;962:103-10.
55. Vincent AM, Brownlee M, Russell JW. Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 2002;959:368-83.
56. Radi R, Rodriguez M, Castro L, et al. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994;308:89-95.
57. Broccolini A, Engel WK, Askanas V. Localization of survival motor neuron protein in human apoptotic-like and regenerating muscle fibers, and neuromuscular junctions. Neuroreport 1999;10:1637-41.
58. Zochodne DW, Verge VM, Cheng C, et al. Nitric oxide synthase activity and expression in experimental diabetic neuropathy. J Neuropathol Exp Neurol 2000;59:798-807.
59. Takeda M, Mori F, Yoshida A, et al. Constitutive nitric oxide synthases is associated with retinal vascular permeability in early diabetic rats. Diabetologia 2001;44:1043-50.
60. Regalia J, Cai F, Helke C. Streptozotocin-induced diabetes and the neurochemistry of vagal afferent neurons. Brain Res 2002;938:7-14.
61. Ito A, Uriu K, Inada Y, et al. Inhibition of neuronal nitric oxide synthase ameliorates renal hyperfiltration in streptozotocin-induced diabetic rat. J Lab Clin Med 2001;138:177-85.
62. Nazli M, Hismiogullari ES, Thippeswamy T, et al. How central is nitric oxide (NO) to the activation of c-fos in spinal neurones following noxious peripheral stimulation in the rat? Brain Res 2001;888:172-5.
63. Thippeswamy T, Morris R. Cyclic guanosine 3′,5′ -monoophosphate-mediated neuroprotection by nitric oxide in dissociated cultures of rat dorsal root ganglion neurones. Brian Res 1997;774:116-22.
64. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-701.
65. Thomas SR, Chen K, Keaney JF Jr. Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redos Signal 2003;5:181-94.
66. Noyman I, Marikovsky M, Sasson S, et al. Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide 2002;7:187-93.
67. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by post-translational modification at the Akt site. J Clin Invest 2001;108:1341-8.
68. Cameron NE, Cotter MA. Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats. Eur J Clin Invest 1995;25:19-24.
69. Stockklauser-Farber K, Ballhausen T, Laufer A, et al. Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta 2000;1535:10-20.
70. Cameron NE, Eaton SE, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-88.
71. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-7.
72. Androne L, Gavan NA, Veresiu IA, et al. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14:327-30.
73. Liang JF, Akaike T. Inhibition of nitric oxide synthesis in primary cultured mouse hepatocytes by alpha-lipoic acid. Chem Biol Interact 2000;124:53-60.
74. Whiteman M, Tritschler H, Halliwell B. Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett 1996;379:74-6.
75. McCarty MF. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium-a key role for selenium-dependent enzymes in vascular health. Med Hypotheses 1999;53:315-25.
76. Visioli F, Smith A, Zhang W, et al. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep 2002;7:223-7.
77. Cameron NE, Cotter MA, Horrobin DH, et al. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 1998;41:390-9.
78. Piotrowski P, Wierzbicka K, Smialek M. Neuronal death in the rat hippocampus in experimental diabetes and cerebral ischaemia treated with antioxidants. Folia Neuropathol 2001;39:147-54.
79. Hounsom L, Horrobin DR, Trischler H, et al. A lipoic acidgamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998;41:839-43.
80. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171-9.
81. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-301.
82. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369-73.
83. Heller R, Unbehaun A, Schellenberg B, et al. L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001;276:40-7.
84. Heller R, Munscher-Paulig F, Grabner R, et al. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 1999;274:8254-60.
85. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr 1995;14:387-92.
86. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31:53-61.
87. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31:53-61.
88. Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000;23:733-8.
89. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 2000;47:475-88.
90. Ceriello A, Bortolotti N, Falleti E, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 1997;20:194-7.
91. Asayama K, Uchida N, Nakane T, et al. Antioxidants in the serum of children with insulin-dependent diabetes mellitus. Free Radic Biol Med 1993;15:597-602.
92. Okuda Y, Kawashima K, Suzuki S et al. Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium. Life Sci 1997;60:L53-6.
93. Obrosova IG. How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002;50:3-35.
94. Yagihashi S, Yamagishi SI, Wada RR, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448-58.
95. Yagihashi S, Kamijo M, Ido Y, et al. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 1990;39:690-6.
96. Sima AAE Prashar A, Nathaniel V, et al. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabet Med 1993;10:115-21.
97. Sima AAE Stevens MJ, Feldman EL, et al. Animal models as tools for the testing of preventive and therapeutic measures in diabetic neuropathy. In: Shafrir E, editor. Lessons from animal diabetes IV. Great Britain: Smith-Gordon; 1993. p. 177-91.
98. Cameron NE, Cotter MA, Basso M, et al. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997;40:271-81.
99. Feldman EL, Stevens MJ, Russell JW, et al. Diabetic neuropathy. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1391-9.
100. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-91.
101. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24:1776-82.
102. Hellweg R, Hartung H-D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258-67.
103. Schmidt RE, Dorsey DA, Beaudet LN, et al. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol 2001;60:263-73.
104. Park DS, Morris EJ, Stefanis L, et al. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 1998;18:830-40.
105. Sampath D, Jackson GR, Werrbach-Perez K, et al. Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. J Neurochem 1994;62:2476-9.
106. Sheehy AM, Phung YT, Riemer RK, et al. Growth factor induction of nitric oxide synthase in rat pheochromocytoma cells. Brain Res Mol Brain Res 1997;52:71-7.
107. Holtzman DM, Kilbridge J, Bredt DS, et al. NOS induction by NGF in basal forebrain cholinergic neurones: evidence for regulation of brain NOS by a neurotrophin. Neurobiol Dis 1994;1:51-60.
108. Tonra JR., Ono M, Liu X, et al. Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Diabetes 1999;48:588-94.
109. Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998;51:695-702.
110. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000;284:2215-21.
111. Skup MH. BDNF and NT-3 widen the scope of neurotrophin activity: pharmacological implications. Acta Neurobiol Exp 1994;54:81-94.
112. Wozniak W. Brain-derived neurotrophic factor (BDNF): role in neuronal development and survival. Folia Morphol 1993;52:173-81.
113. Wellmer A, Misra VP, Sharief MK, et al. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripheral Nerv Syst 2001;6:204-10.
114. Hwang JJ, Choi SY, Koh JY. The role of NADPH oxidase, neuronal nitric oxides synthase and poly(ADP ribose) polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin-4/5. J Neurochem 2002;82:894-902.
115. Klocker N, Kermer P, Gleichmann M, et al. Both the neuronal and inducible isoforms contribute to upregulation of retinal nitric oxide synthase activity by brain-derived neurotrophic factor. J Neurosci 1999;19:8517-27.
116. Yang H, Scheff AJ, Schalch DS. Effects of streptozotocin-induced diabetes mellitus on growth and hepatic insulin-like growth factor I gene expression in the rat. Metabolism 1990;39:295-301.
117. Delaney CL, Feldman EL. Insulin-like growth factor-I and apoptosis in glial cell biology. Neuroscientist 2000;6:39-47.
118. Delaney CL, Cheng H-L, Feldman EL. Insulin-like growth factor-I prevents caspase mediated apoptosis in Schwann cells. J Neurobiol 1999;41:540-8.
119. Ekstrom AR, Kanje M, Skottner A. Nerve regeneration and serum levels of insulin-like growth factor-I in rats with streptozotocin-induced insulin deficiency. Brain Res 1989;496:141-7.
120. Graubert MD, Goldstein S, Phillips LS. Nutrition and somatomedin: XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozocin-induced diabetes. Diabetes 1991;40:959-65.
121. Bornfeldt KE, Arnqvist HJ, Enberg B, et al. Regulation of insulin-like growth factor-I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J Endocrinol 1989;122:651-6.
122. Luo J, Murphy LJ. Differential expression of insulin-like growth factor-I and insulin-like growth factor binding protein-1 in the diabetic rat. Mol Cell Biochem 1991;103:41-50.
123. Zhuang HX, Synder CK, Pu SF, et al. Insulin-likegrowth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996;140:198-205.
124. Schmidt RE, Dorsey DA, Beaudet LN, et al. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am J Pathol 1999;155:1651-60.
125. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992;90:2234-41.
126. Ishii DN. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev 1995;20:47-67.
127. Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-7.
128. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998;102:783-91.
129. Srinivasan S, Stevens MJ, Sheng H, et al. Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells. J Clin Invest 1998;102:1454-62.
130. Migdalis IN, Kalogeropoulou K, Kalantzis L, et al. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med 1995;12:823-7.
131. Vestergaard H, Rossen M, Urhammer SA, et al. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur I Endocrinol 1997;136:475-82.
132. Cheetham TD, Taylor A, Holly IMP, et al. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1994;142:367-74.
133. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999;22:82-8.
134. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002;13:505-12.
135. Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs 1997;54:12-22.
136. Kobayashi N, Higashi T, Hara K, et al. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl, salt-sensitive hypertensive rats. Cardiovasc Res 1999;44:518-26.
137. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-82.
138. de Cavanagh EM, Inserra F, Toblli J, et al. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001;38:1130-6.
139. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-81.